Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis

The favorable outcome of the treatment of a disease is influenced by the adherence to therapy. Our objective was to assess factors associated with adherence to treatment of patients included in a clinical trial of equivalence between the standard and alternative treatment schemes with meglumine antimoniate (MA) in the treatment of cutaneous leishmaniasis (CL), in the state of Rio de Janeiro. Between 2008 and 2011, 57 patients with CL were interviewed using a questionnaire to collect socioeconomic data. The following methods were used for adherence monitoring: counting of vial surplus, monitoring card, Morisky test and modified Morisky test (without the question regarding the schedule); we observed 82.1% (vial return), 86.0% (monitoring card), 66.7% (Morisky test) and 86.0% (modified Morisky test) adherence. There was a strong correlation between the method of vial counting and the monitoring card and modified Morisky test. A significant association was observed between greater adherence to treatment and low dose of MA, as well as with a lower number of people sleeping in the same room. We recommend the use of the modified Morisky test to assess adherence to treatment of CL with MA, because it is a simple method and with a good performance, when compared to other methods.

Download Full-text

Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre

Memórias do Instituto Oswaldo Cruz ◽

10.1590/0074-02760160183 ◽

2016 ◽

Vol 111 (8) ◽

pp. 512-516 ◽

Cited By ~ 17

Author(s):

Rosiana Estéfane da Silva ◽

Antonio Toledo Júnior ◽

Maria Camilo Senna ◽

Ana Rabello ◽

Gláucia Cota

Keyword(s):

Cutaneous Leishmaniasis ◽

Retrospective Review ◽

Referral Centre ◽

Meglumine Antimoniate

Download Full-text

Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis

Dermatology Research and Practice ◽

10.1155/2011/269515 ◽

2011 ◽

Vol 2011 ◽

pp. 1-4 ◽

Cited By ~ 9

Author(s):

Mohamad Javad Yazdanpanah ◽

Mahnaz Banihashemi ◽

Fakhrozaman Pezeshkpoor ◽

Mohammad Khajedaluee ◽

Sororozaman Famili ◽

...

Keyword(s):

Side Effects ◽

Cutaneous Leishmaniasis ◽

Side Effect ◽

Zinc Sulfate ◽

Cure Rate ◽

Meglumine Antimoniate ◽

Treatment Groups ◽

Significant Difference

The purpose of this study was to investigate comparison between oral zinc sulfate and meglumine antimoniate in the treatment of cutaneous leishmaniasis (CL). So 100 patients with CL were included and randomly divided into two groups. The first group was treated with oral zinc sulfate (10 mg/kg/day during 45 days period), and the second group was treated with systemic meglumine antimoniate (20 mg/kg/day intramuscularly for 20 days). Acceptable cure after completing 45 days of followup occurred in 30.2% of lesions in first group, while this was 35.5% for the second group. There is not any significant difference between the two treatment groups (P=0.42). Serious side effects resulting in treatment discounting occurred in only meglumine antimoniate group. Although cure rate of systemic meglumine antimoniate group was better the treatment with zinc sulfate is much easier, cheaper, more convenient in consumption, safer, and nearly close cure percentage to systemic meglumine antimoniate injections without serious side effect.

Download Full-text